Latest news
Debiopharm Group™ Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
Spinomix announces a milestone payment from Debiopharm Group™ and the appointment of a new CEO
BPA Solutions get Investment funds to accelerate rapid growth and global expansion
Atheris and Debiopharm Group™ to collaborate for the lead optimization of Debio 0826 using a “Reverse-Discovery” strategy
Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio…
Experimental Therapeutics Centre and Debiopharm Group™ to collaborate for the development of an epigenetic innovative oncology target
Presented by the Japanese Cancer Association and Debiopharm Group™ the ‘JCA Mauvernay Award 2013’ goes to Doctors Kitabayashi and Yano
Debiopharm Group™ inaugure la « Debiopharm academy » à l’EPFL avec une première conférence sur la médecine personnalisée
Debiopharm Group™ a le plaisir d’annoncer les étudiants choisis pour les Bourses d’excellence
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.